Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway

Atherosclerosis

Volumn 160, Issue 1, 2002, Pages 115-122

  Gabriely, Ilan ^a   Yang, Xiao Man ^a   Cases, Jane A ^a   Ma, Xiao Hui ^a   Rossetti, Luciano ^a   Barzilai, Nir ^a  

^a Institute for Aging Research   (United States)

Author keywords

Diabetes mellitus; Glucose; Hexosamine biosynthetic pathway; Insulin resistance; Obesity; Plasminogen activator inhibitor type 1

Indexed keywords

GLUCOSAMINE; GLUCOSE; HEXOSAMINE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SODIUM CHLORIDE; SOMATOSTATIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLAMP; CONTROLLED STUDY; FIBRINOLYSIS; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE INFUSION; GLUCOSE TRANSPORT; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT;

ADIPOSE TISSUE; ANIMALS; BIOTRANSFORMATION; BLOOD GLUCOSE; BODY COMPOSITION; BODY WEIGHT; GENE EXPRESSION REGULATION; GLUCOSAMINE; HEXOSAMINES; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHLORIDE;

EID: 0036145255     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00574-3     Document Type: Article

References (53)

1. Obesity, atherosclerosis, and coronary artery disease
2. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis
3. The metabolic syndrome X
4. Metabolic syndrome X: A review
5. Haemostatic function and cardiovascular death: Early results of a prospective study
6. Fibrinogen as a risk factor for stroke and myocardial infarction
7. Fibrinogen and cardiovascular risk
8. The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator
9. Plasminogen activator inhibitor 1 (PAI-1) in plasma: Its role in thrombotic disease
10. Haemostatic factors and atherogenesis
11. The status of PAI-1 as a risk factor for arterial and thrombotic disease: A review
12. PAI-1, obesity, insulin resistance and risk of cardiovascular events
13. Immunological relationship between plasminogen activator inhibitors from different sources
14. Induction of type 1 plasminogen activator inhibitor in human liver ischemia and reperfusion
15. Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders
16. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity
17. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and type 2 diabetic subjects
18. Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease
19. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease
20. Up-regulated expression of plasminogen activator inhibitor-1 in Hep G2 cells: Interrelationship between insulin and insulin-like growth factor 1
21. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis
22. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo
23. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo
24. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects
25. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects
26. Beneficial effect of a moderately energy-restricted diet on fibrinolytic factors in non-obese men
27. PAI-1 response to a carbohydrate meal in obese subjects
28. Circadian variation of fibrinolytic activity in blood
29. Hexosamines and insulin resistance
30. Traxinger RR: Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance
31. Overexpression of glutamine: Fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance
32. In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats
33. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat
34. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells
35. Transcriptional regulation of transforming growth factor beta1 by glucose: Investigation into the role of the hexosamine biosynthesis pathway
36. Glucose regulation of transforming growth factor-alpha expression is mediated by products of the hexosamine biosynthesis pathway
37. Glucosamine-induces inhibition of glucokinase impairs the ability of hyperglycemia to suppress endogenous glucose production
38. Role of the glucosamine pathway in fat-induced insulin resistance
39. Assessment of insulin sensitivity in vivo
40. Relative contribution of glycogen synthesis and glycolysis to insulin-mediated glucose uptake. A dose-response euglycemic clamp study in normal and diabetic rats
41. Corrrection of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats
42. Quantitation of glycolysis and skeletal muscle glycogen synthesis in humans
43. Surgical removal of visceral fat in rats reverses hepatic insulin resistance
44. Insulin sensitivity, insulin action, and fibrinolysis activity in nondiabetic and diabetic obese subjects
45. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance
46. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women
47. Influence of changes in lifestyle on fibrinolytic parameters and recurrence rate in patients with venous thromboembolism
48. Regular exercise, plasminogen activator inhibitor-1 (PAI-1) activity and the 4G/5G promoter polymorphism in the PAI-1 gene
49. A high concentration of glucose alters the production of tPA, uPA and PAI-1 antigens from human mesangial cells
50. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose
51. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2
52. The adipocyte and hemostatic balance in obesity: Studies of PAI-1
53. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction